• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Avidity Biosciences Inc.

    8/23/24 5:46:10 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNA alert in real time by email
    SC 13D/A 1 p24-2667sc13da.htm AVIDITY BIOSCIENCES, INC.
    SECURITIES AND EXCHANGE COMMISSION  
       
    Washington, D.C. 20549  
    _______________  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)
     

    Avidity Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    05370A108

    (CUSIP Number)
     

    Eleazer Klein, Esq.

    Adriana Schwartz, Esq.

    919 Third Avenue
    New York, New York 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    August 22, 2024

    (Date of Event which Requires
    Filing of this Schedule)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    (Continued on following pages)

    (Page 1 of 7 Pages)

    --------------------------

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants (as defined in Item 4 of Amendment No. 3))*

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants)*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants)*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    *As more fully described in Item 4, the Shares issuable upon exercise of the Pre-Funded Warrants are subject to a 9.99% beneficial ownership blocker and the percentage set forth on row (13) and the number of Shares set forth on rows (8), (10) and (11) give effect to such blocker.

     

     

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants)*

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants)*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    12,079,734 (including 3,796,864 Shares issuable upon exercise of Pre-Funded Warrants)*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    *As more fully described in Item 4, the Shares issuable upon exercise of the Pre-Funded Warrants are subject to a 9.99% beneficial ownership blocker and the percentage set forth on row (13) and the number of Shares set forth on rows (8), (10) and (11) give effect to such blocker.

     

     

     

     

     

     

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 4 of 7 Pages

     

    This Amendment No. 4 (“Amendment No. 4”) relates to and amends the Statement of Beneficial Ownership on Schedule 13D of the Reporting Persons, initially filed jointly by the Reporting Persons with the Securities and Exchange Commission (“SEC”) on June 22, 2020 (the “Original Schedule 13D”), as amended by Amendment No. 1 filed jointly by the Reporting Persons with the SEC on February 2, 2023 (“Amendment No. 1”), as amended by Amendment No. 2 filed jointly by the Reporting Persons with the SEC on January 24, 2024 (“Amendment No. 2”) and as amended by Amendment No. 3 filed jointly by the Reporting Persons with the SEC on March 1, 2024 (“Amendment No. 3”, and together with the Original Schedule 13D as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3 and this Amendment No. 4, the “Schedule 13D”), with respect to common stock, par value $0.0001 per share (the “Shares”) of the Issuer.

     

    Items 3, 5 (a)-(c) and 6 of the Schedule 13D are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Schedule 13D.

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
       
    Item 3 of the Schedule 13D is hereby amended and restated as follows:
       
    The source of funds used for the purchase of the 8,282,870 Shares reported herein and the Pre-Funded Warrants was the working capital of the RTW Funds.  The aggregate purchase price of the Shares reported herein and the Pre-Funded Warrants is approximately $487,900,589.

     

    Item 5. INTEREST IN SECURITIES OF THE COMPANY.
       
    Items 5 (a)-(c) of the Schedule 13D are hereby amended and restated as follows:
     
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentages of the Shares beneficially owned by the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 117,121,397 Shares outstanding, which is the sum of: (i) the 109,801,397 Shares outstanding as of July 22, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 9, 2024; and (ii) the 7,320,000 Shares to be issued in a public offering as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the SEC on August 15, 2024, and assumes the exercise of the Pre-Funded Warrants subject to the Blocker.
     
    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
     
    (c) The transactions in the Shares effected by the Reporting Persons during the past sixty (60) days, which were all in the open market, are set forth on Schedule 1 attached hereto.

     

     

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 5 of 7 Pages

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
       
    The last paragraph of Item 6 of Amendment No. 3 is hereby amended and restated as follows:
     

    Since the filing of the Schedule 13D, the Reporting Persons have acquired and disposed of cash-settled swaps that constitute long economic exposure to the Shares (“Long TRS Positions”). Currently the Long TRS Positions of the Reporting Persons constitute long economic notional exposure to 900,000 Shares or approximately 0.8% of the outstanding Shares in the aggregate. All balances due under the swaps will be cash settled on the applicable settlement date and may not be settled by the delivery of Shares. In addition, the swaps do not give any of the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer, do not provide the Reporting Persons with an option to purchase any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. The Reporting Persons do not have voting power or dispositive power with respect to the Shares referenced in such cash settled swaps and disclaim beneficial ownership of the to which such swaps relate.

     

    In addition, Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following:

     

    The Reporting Persons have a short position that represents 143,556 Shares, which is approximately 0.1% of the Shares outstanding.

     

     

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 6 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    DATED:  August 23, 2024
     
    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

     

     

     

     

     

    CUSIP No. 05370A108SCHEDULE 13D/APage 7 of 7 Pages

    Schedule 1

     

    This Schedule sets forth information with respect to each purchase and sale of Shares which were effectuated by the Reporting Persons during the past sixty (60) days. All transactions were effectuated in the open market through a broker. The price reported in the column Price Per Share ($) is a weighted average price if a price range is indicated in the column Price Range ($). These Shares were purchased/sold in multiple transactions at prices between the price ranges below. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of Shares sold at each separate price.

     

    Trade Date

    Shares Purchased

    (Sold)

    Price ($)* Price Range ($)*
    06/24/2024 (28,933)** 40.0000  
    06/25/2024 (128,972)** 40.4575 40.1869-40.8000
    06/26/2024 (5,000)** 40.0001  
    06/27/2024 (297,266)** 40.4813 40.2000-40.9836
    06/28/2024 (500,000) 40.8500  
    06/28/2024 (105,000)** 41.0190 41.0000-41.0374
    07/01/2024 (225,000)** 41.0538 41.0000-41.2421
    07/09/2024 (92,902)** 40.1616 40.0230-40.4815
    07/10/2024 (150,000)** 41.4347 41.0090-41.7729
    07/10/2024 (255,000)** 42.3729 42.0000-42.5344
    07/11/2024 (409,423)** 44.2089 43.5592-44.5278
    07/12/2024 (233,392)** 44.5726 44.5017-44.8128
    07/15/2024 (209,910)** 45.5431 45.2006-45.7571
    07/15/2024 (600,000) 45.6200  
    07/15/2024 600,000*** 45.6200  
    07/16/2024 (355,958)** 46.6329 46.1414-46.7739
    07/17/2024 (125,000)** 46.3345 46.0229-46.7167
    07/18/2024 (121,980)** 45.8136 45.4978-46.0172
    07/19/2024 (125,917)** 45.0449 45.0105-45.1750
    07/22/2024 (378,034)** 46.0810 45.5020-46.3763
    07/23/2024 (185,900)** 46.6228 46.5012-47.0000
    07/24/2024 (21,306)** 45.8840  
    07/25/2024 (315,000) 45.8929 45.8001-46.2500
    07/25/2024 (111,630)** 46.0600 45.5149-46.5030
    07/30/2024 (23,762) 45.5047  
    07/31/2024 (130,938) 45.7311 45.5124-46.0000
    08/01/2024 (100,000) 46.0041  
    08/09/2024 (255,279) 46.5587 46.0000-47.0000
    08/12/2024 (7,738) 45.0596  
    08/13/2024 (102,195) 45.1098 45.0058-45.3155
    08/14/2024 (13,605) 43.0001 43.0000-43.0005
    08/15/2024 (300,000) 44.8524 44.0390-45.0276
    08/15/2024 (417,199) 45.5450 45.4793-45.7997
    08/16/2024 (42,064) 45.0919 45.0000-45.1157
    08/19/2024 (321,389) 45.4286 45.3745-45.5096
    08/20/2024 (11,602) 45.0670  
    08/21/2024 (189,333) 45.7628 45.5000-46.0000
    08/22/2024 (4,529,103) 42.8550  
    08/22/2024 1,922,967*** 42.8550  
    08/22/2024 2,606,136 42.8550  

     

     

    * Excluding commissions, SEC fees, etc. (rounded to nearest cents).

    ** Short sale.

    *** Buy to cover.

     

     

     

     

    Get the next $RNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNA

    DatePrice TargetRatingAnalyst
    3/13/2025$70.00Buy
    Citigroup
    3/12/2025$72.00Outperform
    BMO Capital Markets
    3/7/2025$70.00Sector Outperform
    Scotiabank
    12/20/2024$72.00Buy
    H.C. Wainwright
    11/26/2024$67.00Outperform
    RBC Capital Mkts
    9/24/2024$59.00Buy
    Goldman
    8/28/2024$63.00Overweight
    Barclays
    5/3/2024$40.00Buy
    BofA Securities
    More analyst ratings

    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Program Officer Gallagher Kathleen P. exercised 5,875 shares at a strike of $16.65 and sold $190,324 worth of shares (5,875 units at $32.40) (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      5/2/25 7:55:34 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Program Officer Gallagher Kathleen P. exercised 5,875 shares at a strike of $14.81 and sold $163,486 worth of shares (5,875 units at $27.83) (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      4/3/25 4:56:11 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Hughes Steven George sold $297,491 worth of shares (9,578 units at $31.06), decreasing direct ownership by 12% to 72,850 units (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      3/21/25 6:44:16 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

      SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

      11/14/24 5:46:11 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

      SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

      11/14/24 1:22:38 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avidity Biosciences Inc.

      SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

      11/14/24 9:39:22 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNA
    Financials

    Live finance-specific insights

    See more

    $RNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RNA
    SEC Filings

    See more

    $RNA
    Leadership Updates

    Live Leadership Updates

    See more

    $RNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting

      Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates

      3/30/23 7:07:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

      Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A

      9/27/22 7:00:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Avidity Biosciences with a new price target

      Citigroup initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $70.00

      3/13/25 8:20:06 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Avidity Biosciences with a new price target

      BMO Capital Markets initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $72.00

      3/12/25 7:32:18 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Avidity Biosciences with a new price target

      Scotiabank initiated coverage of Avidity Biosciences with a rating of Sector Outperform and set a new price target of $70.00

      3/7/25 8:17:18 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Avidity Biosciences Inc.

      10-Q - Avidity Biosciences, Inc. (0001599901) (Filer)

      5/8/25 4:08:29 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

      5/8/25 4:06:34 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Avidity Biosciences Inc.

      DEFA14A - Avidity Biosciences, Inc. (0001599901) (Filer)

      4/29/25 4:04:41 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

      SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh

      8/5/24 9:00:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

      On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD  Executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in U.S. in 2026 Strong balance sheet supports execution across three late-stage clinical programs and commercial launch preparations with cash runway into mid-2027 SAN DIEGO, May 8, 2025 /PRNewswire/ -- Avidity Biosc

      5/8/25 4:05:00 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences to Participate in Upcoming Investor Conference

      SAN DIEGO, May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ETLive webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the

      5/6/25 9:00:00 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the empl

      4/21/25 4:05:00 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care